Guardian Bio
Dendritic cell-based platform for cancer therapy
ActiveSummer 2022Biotech
About Guardian Bio
Dendritic cell-based platform for cancer therapy
Risk Analysis
Category Risk
13%death rate
Biotech: 18 of 140 startups failed
LOWTeam Size
2people
Median for failed in Biotech: 6
Median for active in Biotech: 5
External Resources
Read full post-mortem on startups.rip ↗(opens in new tab)Website ↗(opens in new tab)YC Profile ↗(opens in new tab)Report data issue
Post-mortem content hosted on startups.rip — we provide the analytics layer.